COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy.
Giuseppe Novelli,Giuseppe Novelli,Michela Biancolella,Ruty Mehrian-Shai,Vito Luigi Colona,Anderson F. Brito,Nathan D. Grubaugh,Vasilis Vasiliou,Lucio Luzzatto,Juergen K. V. Reichardt +9 more
Reads0
Chats0
TLDR
The authors in this article reviewed the current state at the milestone of 1 year into the pandemic, as declared by the WHO (World Health Organization), focusing first on two major topics: viral variants and the human genetic susceptibility to disease severity.Abstract:
COVID-19 has engulfed the world and it will accompany us all for some time to come. Here, we review the current state at the milestone of 1 year into the pandemic, as declared by the WHO (World Health Organization). We review several aspects of the on-going pandemic, focusing first on two major topics: viral variants and the human genetic susceptibility to disease severity. We then consider recent and exciting new developments in therapeutics, such as monoclonal antibodies, and in prevention strategies, such as vaccines. We also briefly discuss how advances in basic science and in biotechnology, under the threat of a worldwide emergency, have accelerated to an unprecedented degree of the transition from the laboratory to clinical applications. While every day we acquire more and more tools to deal with the on-going pandemic, we are aware that the path will be arduous and it will require all of us being community-minded. In this respect, we lament past delays in timely full investigations, and we call for bypassing local politics in the interest of humankind on all continents.read more
Citations
More filters
Journal ArticleDOI
Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.
Paul Bastard,Adrian Gervais,Adrian Gervais,Tom Le Voyer,Tom Le Voyer,Jérémie Rosain,Jérémie Rosain,Quentin Philippot,Quentin Philippot,Jeremy Manry,Jeremy Manry,Eleftherios Michailidis,Hans-Heinrich Hoffmann,Shohei Eto,Marina Garcia-Prat,Lucy Bizien,Lucy Bizien,Alba Parra-Martínez,Rui Yang,Liis Haljasmägi,Mélanie Migaud,Mélanie Migaud,Karita Särekannu,Julia Maslovskaja,Nicolas de Prost,Yacine Tandjaoui-Lambiotte,Charles-Edouard Luyt,Charles-Edouard Luyt,Blanca Amador-Borrero,Alexandre Gaudet,Julien Poissy,Pascal Morel,Pascale Richard,Fabrice Cognasse,Jesús Troya,Sophie Trouillet-Assant,Alexandre Belot,Alexandre Belot,Kahina Saker,Pierre Garçon,Jacques G. Rivière,Jean-Christophe Lagier,Stéphanie Gentile,Lindsey B. Rosen,Elana Shaw,Tomohiro Morio,Junko Tanaka,David Dalmau,Pierre-Louis Tharaux,Damien Sène,Alain Stepanian,Bruno Mégarbane,Vasiliki Triantafyllia,Arnaud Fekkar,James R. Heath,José Luis Franco,Juan-Manuel Anaya,Jordi Solé-Violán,Luisa Imberti +58 more
TL;DR: In this paper, the authors found that auto-antibodies neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections.
Journal ArticleDOI
Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19.
Xavier Solanich,Gardenia Vargas-Parra,Caspar I van der Made,Annet Simons,Janneke H M Schuurs-Hoeijmakers,Arnau Antolí,Jesús del Valle,Gemma Rocamora-Blanch,Fernando Setien,Manel Esteller,Simon V. van Reijmersdal,Antoni Riera-Mestre,Antoni Riera-Mestre,Joan Sabater-Riera,Gabriel Capellá,Frank L. van de Veerdonk,Ben van der Hoven,Xavier Corbella,Xavier Corbella,Alexander Hoischen,Conxi Lázaro +20 more
TL;DR: In this paper, the TLR7 missense variants were identified in two out of 14 patients (14.3%) and were not previously reported in population control databases and were predicted to be damaging by in silico predictors.
Journal ArticleDOI
Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Xavier Solanich,Raül Rigo-Bonnin,Victor-David Gumucio,Paul Bastard,Paul Bastard,Paul Bastard,Jérémie Rosain,Jérémie Rosain,Quentin Philippot,Quentin Philippot,Xose-Luís Pérez-Fernández,Maria-Paz Fuset-Cabanes,Miguel-Ángel Gordillo-Benitez,Guillermo Suarez-Cuartin,Enric Boza-Hernandez,Antoni Riera-Mestre,Alba Parra-Martínez,Roger Colobran,Arnau Antolí,Sergio Navarro,Gemma Rocamora-Blanch,Mario Framil,Laura Calatayud,Xavier Corbella,Jean-Laurent Casanova,Francisco Morandeira,Joan Sabater-Riera +26 more
TL;DR: In this paper, an analysis of COVID-19 patients admitted to an intensive care unit (ICU) in which samples were available, from March 2020 to March 2021, in Barcelona, Spain, was conducted.
Journal ArticleDOI
COVID-19 2022 update: transition of the pandemic to the endemic phase
Michela Biancolella,Vito Luigi Colona,Ruty Mehrian-Shai,Jessica Watt,Lucio Luzzatto,Giuseppe Novelli,Juergen K. V. Reichardt +6 more
TL;DR: In this paper , the authors reviewed the current state of research into the disease with focus on its history, human genetics and genomics and the transition from the pandemic to the endemic phase.
Journal ArticleDOI
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Meng Zhang,Ying Liang,Dongsheng Yu,Bang Du,Weyland Cheng,Lifeng Li,Zhidan Yu,Shuying Luo,Yaodong Zhang,Huanmin Wang,Xianwei Zhang,Wancun Zhang +11 more
TL;DR: Key points on the future SARS-CoV-2 vaccine research and development are discussed, hoping to make a contribution to the early, accurate and rapid control of the COVID-19 epidemic.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Direct gene transfer into mouse muscle in vivo.
Jon A. Wolff,Robert W. Malone,Phillip Williams,Wang Chong,Gyula Acsadi,Agnes Jani,Philip L. Felgner +6 more
TL;DR: RNA and DNA expression vectors containing genes for chloramphenicol acetyltransferase, luciferase, and beta-galactosidase were separately injected into mouse skeletal muscle in vivo and expression was comparable to that obtained from fibroblasts transfected in vitro under optimal conditions.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Related Papers (5)
Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future.
Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang,Paul Bastard,Paul Bastard,Zhiyong Liu,Jérémie Le Pen,Marcela Moncada-Vélez,Jie Chen,Masato Ogishi,Ira K. D. Sabli,Stephanie Hodeib,Cecilia B. Korol,Jérémie Rosain,Jérémie Rosain,Kaya Bilguvar,Junqiang Ye,Alexandre Bolze,Benedetta Bigio,Rui Yang,Andrés Augusto Arias,Andrés Augusto Arias,Qinhua Zhou,Yu Zhang,Fanny Onodi,Sarantis Korniotis,Léa Karpf,Quentin Philippot,Quentin Philippot,Marwa Chbihi,Marwa Chbihi,Lucie Bonnet-Madin,Karim Dorgham,Nikaïa Smith,William M. Schneider,Brandon S. Razooky,Hans-Heinrich Hoffmann,Eleftherios Michailidis,Leen Moens,Ji Eun Han,Lazaro Lorenzo,Lazaro Lorenzo,Lucy Bizien,Lucy Bizien,Philip Meade,Anna-Lena Neehus,Anna-Lena Neehus,Aileen Camille Ugurbil,Aurélien Corneau,Gaspard Kerner,Gaspard Kerner,Peng Zhang,Franck Rapaport,Yoann Seeleuthner,Yoann Seeleuthner,Jeremy Manry,Jeremy Manry,Cécile Masson,Yohann Schmitt,Agatha Schlüter,Tom Le Voyer,Tom Le Voyer,Taushif Khan,Juan Li,Jacques Fellay,Jacques Fellay,Lucie Roussel,Mohammad Shahrooei,Mohammed F. Alosaimi,Davood Mansouri,Haya Al-Saud,Fahd Al-Mulla,Feras M. Almourfi,Saleh Al-Muhsen,Fahad Alsohime,Saeed Al Turki,Rana Hasanato,Diederik van de Beek,Andrea Biondi,Laura Rachele Bettini,Mariella D'Angiò,Paolo Bonfanti,Luisa Imberti,Alessandra Sottini,Simone Paghera,Eugenia Quiros-Roldan,Camillo Rossi,Andrew J. Oler,Miranda F. Tompkins,Camille Alba,Isabelle Vandernoot,Jean-Christophe Goffard,Guillaume Smits,Isabelle Migeotte,Filomeen Haerynck,Pere Soler-Palacín,Andrea Martín-Nalda,Roger Colobran,Pierre-Emmanuel Morange,Sevgi Keles,Fatma Çölkesen,Tayfun Ozcelik,Kadriye Kart Yaşar,Sevtap Şenoğlu,Şemsi Nur Karabela,Carlos Rodríguez-Gallego,Giuseppe Novelli,Sami Hraiech,Yacine Tandjaoui-Lambiotte,Xavier Duval,Xavier Duval,Cédric Laouénan,Cédric Laouénan,Covid-Storm Clinicians§,Covid Clinicians,CoV-Contact Cohort§,CoV-Contact Cohort§,Amsterdam Umc Covid Biobank,Covid Human Genetic Effort,Niaid-Usuhs,Niaid-Usuhs,Niaid-Usuhs,Andrew L. Snow,Clifton L. Dalgard,Joshua D. Milner,Donald C. Vinh,Donald C. Vinh,Trine H. Mogensen,Trine H. Mogensen,Nico Marr,András N Spaan,András N Spaan,András N Spaan,Bertrand Boisson,Bertrand Boisson,Bertrand Boisson,Stéphanie Boisson-Dupuis,Jacinta Bustamante,Jacinta Bustamante,Jacinta Bustamante,Anne Puel,Michael J. Ciancanelli,Isabelle Meyts,Tom Maniatis,Vassili Soumelis,Ali Amara,Ali Amara,Michel C. Nussenzweig,Adolfo García-Sastre,Florian Krammer,Aurora Pujol,Darragh Duffy,Darragh Duffy,Richard P. Lifton,Richard P. Lifton,Richard P. Lifton,Shen-Ying Zhang,Guy Gorochov,Guy Gorochov,Guy Gorochov,Vivien Béziat,Vivien Béziat,Vivien Béziat,Emmanuelle Jouanguy,Vanessa Sancho-Shimizu,Charles M. Rice,Charles M. Rice,Charles M. Rice,Laurent Abel,Luigi D. Notarangelo,Luigi D. Notarangelo,Luigi D. Notarangelo,Aurélie Cobat,Helen C. Su,Jean-Laurent Casanova +172 more